Search

Aims: The SURMOUNT‐1 trial investigated effects of tirzepatide, a glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist, on body weight in participants with obesity or overweight. This analysis evaluated changes in patient‐reported outcomes (PROs) assessing physical function, psychosocial well‐being, and overall health aspects of participants' health‐related quality of life (HRQoL) in SURMOUNT‐1. Methods: PRO instruments included the Impact of Weight on Quality of Life‐Lite Clinical Trials version (IWQOL‐Lite‐CT), Short Form Survey‐36 version 2 (SF‐36v2) and EQ‐5D‐5L. Scores were analysed by treatment group and by categorical degree of weight reduction group: >0 to <5%, ≥5 to <10%, ≥10 to <20% and ≥20%. Relevant PROs were evaluated for participants with or without physical or psychosocial limitations at baseline, as measured by Patient Global Impression of Status for physical activity (PGIS) and Patient Health Questionnaire‐2 (PHQ‐2), respectively. Results: All tirzepatide groups demonstrated significant improvements in PRO scores versus placebo. There was a consistent trend of incremental PRO improvement with greater degrees of weight reduction, starting from ≥5% weight reduction. Participants achieving ≥20% weight reduction demonstrated the greatest changes from baseline to week 72 (SF‐36v2 Physical Component Summary, 4.60; SF‐36v2 Mental Component Summary, 0.80; IWQOL‐Lite CT Total score, 24.7). Those with baseline physical and psychosocial limitations experienced greater improvements than those without. Conclusions: Tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity. Higher percentages of weight reduction were associated with greater improvements. Clinical trial registration number for SURMOUNT‐1: NCT04184622. [ABSTRACT FROM AUTHOR]

Background: Individuals with overweight or obesity often endure significant weight‐based prejudice and discrimination in various settings. Experiencing weight‐related stigma is linked to many adverse psychosocial outcomes. Weight self‐stigma is when an individual internalizes and identifies with negative attributes ascribed to people with larger bodies and has self‐devaluing thoughts because of their weight and is associated with poorer health outcomes. Aims: This study explored how weight self‐stigma may impact weight management efforts and outcomes for adults participating in an onlight weight‐loss intervention. Materials and Methods: 508 adults (86.2% female, 84.6% White) with overweight or obesity participated in an asynchronous 12‐week online weight‐loss intervention with computer‐generated feedback. Weight and weight self‐stigma were measured at baseline and 3 months later. Results: Thirty‐one point five percent of the sample reported high levels of stigma, which was associated with greater program dropout than those who did not report high stigma (32.5% vs. 21.6%). Program completers reporting high self‐stigma showed better treatment engagement (77.0% vs. 69.7% lessons viewed) and weight loss (M = −6.31% vs. −5.08%); these differences were not observed when using intent‐to‐treat assumptions. When analyzed as a continuous variable, weight self‐stigma showed no association with treatment engagement and outcome. Discussion: These findings highlight the complexity of understanding how self‐stigma affects treatment engagement and outcome in behavioral weight loss and the need for more targeted research in this understudied area. Conclusion: Results suggest that weight self‐stigma plays a role in weight management during an online weight‐loss intervention, affecting engagement and outcomes. [ABSTRACT FROM AUTHOR]

Copyright of Revista Foco (Interdisciplinary Studies Journal) is the property of Revista Foco and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Quality glucose-like peptide-1 receptor agonist (GLP-1 RA)-supported digital weight-loss services (DWLSs) have the potential to play a significant role in shifting the alarming global obesity rate. Previous studies have demonstrated various aspects of their utility in Australian and British populations, but nothing has hitherto been investigated in real-world European settings, where GLP-1 RA weight therapy and digital healthcare are widely used. This study retrospectively analysed the 5-month (Mean = 160.14 days) weight-loss outcomes in a cohort of patients who received email-based health coaching and Semaglutide therapy via the Juniper Germany DWLS (n = 833). Mean weight loss was 9.52 (±5.46) percent, with 81.51% of the cohort losing a 'meaningful' (5% or more) amount of weight. Females (Mean = 9.75) tended to lose more weight than males (Mean = 8.41) and patients from the lowest two BMI categories (27.5–29.99 kg/m2 Mean = 10.1; 30–34.99 kg/m2 Mean = 9.74) lost significantly more weight than those in the highest BMI category (≥40 kg/m2 Mean = 8.11). These findings indicate that GLP-1 RA-supported DWLSs can contribute to meaningful weight loss in Germany. Future research should seek to conduct a dedicated adherence analysis of the Juniper Germany DWLS and measure the effect of subsidisation and baseline body mass index on general DWLS effectiveness. [ABSTRACT FROM AUTHOR]

Objective: The objective of this study was to evaluate the efficacy of a mobile health (mHealth)‐delivered behavioral intervention on changes in postpartum weight and cardiometabolic risk factors (blood pressure [BP], lipids, and hemoglobin A1c) over 12 months. Methods: A randomized controlled trial of 300 African American postpartum people with overweight and obesity enrolled in Philadelphia Women, Infants, and Children (WIC) clinics was conducted. Participants were randomized to usual WIC care (n = 151) or a 12‐month mHealth‐delivered intervention (n = 149) comprising behavior change goals, interactive self‐monitoring text messages, and counseling support. Results: Intervention and usual‐care participants did not significantly differ in 12‐month mean postpartum weight change (1.1 vs. 1.6 kg, p = 0.5; difference −0.6 kg, 95% CI: −2.3 to 1.2). However, high intervention engagement led to weight loss compared with weight gain among those who were less engaged (−0.6 vs. 2.4 kg, p = 0.01; difference −3.0 kg, 95% CI: −5.4 to −0.6). The intervention reduced systolic BP relative to usual care (−1.6 vs. 2.4 mm Hg, p = 0.02; difference −4.0 mm Hg, 95% CI: −7.5 to −0.5), but this effect did not extend to other cardiometabolic risk factors. Conclusions: Among African American postpartum people enrolled in WIC, an mHealth‐delivered intervention reduced systolic BP but not additional cardiometabolic risk factors or weight. Intervention participants with high engagement had significantly better postpartum weight outcomes, and thus, next steps include addressing barriers to engagement. [ABSTRACT FROM AUTHOR]

Background: Coaching on Lifestyle (CooL) is a two-year healthcare intervention for people with overweight or obesity, stimulating weight reduction by promoting sustained healthier behavior. The objective of this study is to investigate the effects of CooL on participants' anthropometrics, personal factors and behavioral factors over the two-year timeframe of CooL. Methods: A descriptive case series study, using a broad set of routinely collected data on anthropometrics, personal factors and behavioral factors of adults living across the Netherlands. The data were collected between November 2018 and December 2021 among participants of CooL (N = 746) at three moments during the intervention: at baseline (T0), at 8 months (T1) after completion of phase 1 and at 24 months (T2) after ending CooL. Changes over time were analyzed using paired t-tests comparing baseline to T1 and baseline to T2. In addition, potential differences on outcomes in subgroups based on education level, weight status and group size were examined using paired t-tests and ANOVA-tests. Results: The results showed positive changes on all outcomes at 24 months compared to baseline. The largest effects were on perceived health, attentiveness towards meal size and meal composition (large effect size). Mean weight loss was 4.13 kg (SD 7.54), and mean waist circumference decreased with 4.37 centimeters (SD 8.59), indicating a medium to large effect size. Changes were consistent across subgroups varying in educational level, BMI at baseline and group size. Conclusion: The study demonstrated sustained weight-related effects of CooL over 24 months supporting its two-year duration. The results indicate that CooL, though not for every individual, is in general appropriate and effective for different group sizes and for a wide variety of participants regardless of level of education, or BMI at baseline. Trial registration: Dutch Trial Register NTRNL6061 (13-01-2017). Registered at Overview of Medical Research in the Netherlands (OMON), via https://www.onderzoekmetmensen.nl/. [ABSTRACT FROM AUTHOR]

Background: Most obese people do not have high self-esteem. This study was conducted to evaluate the effect of self-esteem education on the weight status of obese women. Methods: This Randomized Clinical Trial (RCT) was performed on 46 obese women (BMI >30) in Hamadan during 2021–2022. By simple convenient sampling and block randomization, the samples were divided into two equal groups. In both groups, routine lifestyle and diet recommendations were prescribed. In the intervention group, eight sessions of self-esteem training were performed specifically. In two groups BMI was measured and the Cooper-Smith Self-Esteem Inventory (CSEI) was filled out before and after the intervention. SPSS 20 was used to analyze the data. Statistical significance was considered at p < 0.05. Results: The mean age of the participants in the intervention and control groups was 27.95 (5.02) and 30.25 (5.46) years respectively (t38 = 1.39, p = 0.17). BMI was comparable in two groups before the study (32.47 vs. 33.13 in the intervention and control group respectively, (t38 = 1.02, p = 0.31), but decreased significantly in the intervention group at the end (30.38 vs. 32.90, t38 = 3.76, p = 0.001). The mean self-esteem scores of the two groups were similar at the beginning (27.10 vs. 27.60 in the intervention and control group respectively, (t38 = 0.52, p = 0.60) but increased significantly in the intervention group at the end (30.10 vs. 27.35, t38 = 2.99, p < 0.001). Conclusions: The findings suggest that self-esteem educational programs can increase the self-esteem score and decrease BMI in obese women and should be considered as a treatment modality in these women. [ABSTRACT FROM AUTHOR]

Bariatric surgery (BS) is a leading treatment for obesity; however, adverse side effects (e.g., pain and infection) can deter patients or affect weight maintenance. This study investigates how a post-operative virtual health coaching lifestyle program, monitoring virtual weekly goal progress made by patients, affects weight loss after BS, specifically sleeve gastrectomy. Patients recruited for this 6-month study were classified with a BMI > 30 kg/m2 90 days post-operatively. Patients were prescribed lifestyle support delivered by certified health and wellness coaches (InHealth Lifestyle Therapeutics™). Demographic variables (e.g., age, weight, height, and gender) were obtained and compared according to initial, 3-, 6-month, and current weight through repeated measures ANOVA and post hoc comparison. Thirty-eight adult participants were included, with a mean age of 52 years ± 12.9 and with a majority (n = 35; 97%) of them being female. There were significant differences in weight reported across all five time points (p < 0.05), with the greatest weight difference seen between the initial (250.3 ± 45.5 lbs.) and final time points (226.7± 40.4 lbs.). This study suggests post-operative virtual health coaching can enhance weight loss outcomes after sleeve gastrectomy. Further research is needed to assess the long-term effects and cost-effectiveness of such a form of coaching for bariatric surgery patients. [ABSTRACT FROM AUTHOR]

Increasingly large numbers of people are using digital weight loss services (DWLSs) to treat being overweight and obesity. Although it is widely agreed that digital modalities improve access to care in general, obesity stakeholders remain concerned that many DWLSs are not comprehensive or sustainable enough to deliver meaningful health outcomes. This study adopted a mixed methods approach to assess why and after how long patients tend to discontinue Australia's largest DWLS, a program that combines behavioural and pharmacological therapy under the guidance of a multidisciplinary care team. We found that in a cohort of patients who commenced the Eucalyptus DWLS between January and June 2022 (n = 5604), the mean program adherence was 171.2 (±158.2) days. Inadequate supplying of a patient's desired glucose-like peptide-1 receptor agonist medication was the most common reason for discontinuation (43.7%), followed by program cost (26.2%), result dissatisfaction (9.9%), and service dissatisfaction (7.2%). Statistical tests revealed that ethnicity and age both had a significant effect on patient adherence. These findings suggest that DWLSs have the potential to improve access to comprehensive, continuous obesity care, but care models need to improve upon the one observed in the Eucalyptus Australia DWLS to mitigate common real-world program attrition factors. [ABSTRACT FROM AUTHOR]

The following cases demonstrate a proof of concept for the safe and effective use of the glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) semaglutide for weight loss in obese, non‐diabetic, end stage kidney disease (ESKD) patients on haemodialysis (HD), who are unable to undergo renal transplantation due to obesity. Obesity is a common barrier to wait‐listing for renal transplantation with effective, broadly applicable weight loss strategies lacking. GLP‐1 RAs have been shown to be effective adjuncts to achieve weight loss in non‐diabetic obese people. However, the major clinical trials excluded patients with ESKD on dialysis. This paper outlines the successful use of semaglutide to achieve a target body mass index (BMI) prior to renal transplant wait‐listing in two obese, non‐diabetic, HD patients. These patients achieved a 16% and 12.6% weight loss in under 9 months with one now waitlisted and the other transplanted. This strategy has the potential for broader use in this patient cohort to improve wait‐list times by overcoming this common barrier to renal transplantation. [ABSTRACT FROM AUTHOR]

Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome, making it challenging to improve prognosis with pharmacotherapy. Obesity is one of the leading phenotypes of HFpEF, and its prevalence continues to grow worldwide. Consequently, obesity-targeted interventions have attracted attention as a novel treatment strategy for HFpEF. The authors review the association between the pathogenesis of obesity and HFpEF and the potential for obesity-targeted pharmacotherapeutic strategies in HFpEF, together with the latest evidence. The literature search was conducted in PubMed up to April 2024. The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients, along with a substantial weight loss. Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 43-year-old patient who underwent bariatric surgery abroad. It mentions that, initially, the surgery was without complications, but upon returning to the United Kingdom, the patient faced severe wound healing problems and psychological distress. It highlights the risks and challenges associated with medical tourism for bariatric procedures.

The issues involving obesity are multifactorial. The most common orientation about it is to encourage weight loss. However, the summary of this disease only to its biological aspects has not been effective. The objective of this work was to bring up a reflection about the obstacles that hinder the health care of people with obesity. This is a narrative and reflective review of propositions that do not relate solely to the biological point of view of obesity. A discussion was built about the stigmas that hinder the guarantee of health for fat people. It is noticed that the use of the BMI tool is not effective individually, being indicated the new percentage weight loss classification, referring to the history of greater weight. In addition, the recommendation is to discourage restrictive diets, provide guidance on eating behaviors, offer stigma-free support from healthcare professionals and ensure access to integral and humanized health. [ABSTRACT FROM AUTHOR]

The article explores the rising significance of GLP-1 receptor agonists, notably semaglutide, in revolutionizing obesity treatment. It highlights their efficacy in weight loss and potential cardiovascular benefits, and discusses their market growth projections and the challenges posed by off-label use and supply shortages. It underscores the promising future of obesity treatment with ongoing research into long-term weight management solutions.

Background: Weight recurrence (WR) affects nearly 20% of patients after bariatric surgery and may decrease its benefits, affecting patients' quality of life negatively. Patient perspectives on WR are not well known. Objectives: Assess patient needs, goals, and preferences regarding WR treatment. Setting: Single MBSAQIP-accredited academic center, and online recruitment. Methods: An 18-item, web-based survey was distributed to adults seeking treatment for WR after a primary bariatric surgery (PBS), in addition to online recruitment, between 2021 and 2023. Survey items included somatometric data, questions about the importance of factors for successful weight loss, procedure decision-making, and treatment expectations. Results: Fifty-six patients with > 10% increase from their nadir weight were included in the study. Patients had initially undergone Roux-en-Y gastric bypass (62.5%), sleeve gastrectomy (28.6%), adjustable gastric banding (3.6%), or other procedures (5.3%). When assessing their satisfaction with PBS, 57.1% were somewhat/extremely satisfied, 33.9% somewhat/extremely dissatisfied, while 8.9% were ambivalent. Patients considered the expected benefits (for example, weight loss) as the most important factor when choosing a treatment option for WR. Patient goals included "feeling good about myself" (96.4% very/extremely important), "being able to resume activities I could not do before" (91% very/extremely important), and "improved quality of life" and "-life expectancy" (> 90% very/extremely important). Finally, RBS, lifestyle modification with peer support, and anti-obesity medication were ranked as first treatment options for WR by 40%, 38.8%, and 29.8% of the respondents, respectively. Conclusions: Patients considered weight loss as the most important factor when choosing treatment modality for WR, with RBS and lifestyle changes being preferred over weight-loss medications. Large prospective randomized trials are needed to counsel this patient population better. [ABSTRACT FROM AUTHOR]

Objective: Obesity adversely impacts breast cancer treatment and outcomes. This study assessed the efficacy of nurses' motivational interviews (MI) in promoting weight loss among breast cancer patients. Methods: Motivational Interviewing was performed at 4, 8, and 12 weeks from baseline in 27 overweight/obese breast cancer patients receiving adjuvant endocrine therapy. An average weight loss rate of 5% at week 12 was the threshold for determining whether MI intervention was clinically meaningful. Clinical and sociodemographic variables were gathered from medical records and self-administered questionnaires. Body weight, body mass index (BMI), physical activity time, sedentary time, self-efficacy for weight loss, and mood scores were evaluated at baseline, 4, 8, 12, and 24 weeks. Results: Significant reductions in body weight were observed throughout compared with baseline; 51.9% of participants attained the 5% weight loss target, but the average weight loss rate was 3.9% at week 12. BMI notably decreased at 8, 12, and 24 weeks compared with baseline. Physical activity increased significantly at 12 weeks, while sedentary time decreased at 8 and 24 weeks. Conclusions: Nursing-administered MI did not achieve the goal of 5% weight loss at week 12. However, it increased physical activity and reduced sedentary time, showing potential for promoting healthier habits. [ABSTRACT FROM AUTHOR]

This article explores the challenges of accurately measuring kidney outcomes in obese individuals who undergo significant weight loss. It focuses on the use of GLP1-RA and dual GLP1/GIP-receptor agonists for the treatment of type 2 diabetes and obesity, which have shown positive effects on renal outcomes. However, measuring glomerular filtration rate (GFR) and urinary albumin excretion (UAE) in obese individuals can be complex. Factors such as muscle mass and weight loss can affect the accuracy of filtration markers like creatinine and cystatin-C, and indexing GFR to body surface area (BSA) may not account for increased body size. The article emphasizes the need for more accurate methods of measuring kidney outcomes in obese individuals with weight loss. [Extracted from the article]

Background: Research implicates inflammation in the vicious cycle between depression and obesity, yet few longitudinal studies exist. The rapid weight loss induced by bariatric surgery is known to improve depressive symptoms dramatically, but preoperative depression diagnosis may also increase the risk for poor weight loss. Therefore, we investigated longitudinal associations between depression and inflammatory markers and their effect on weight loss and clinical outcomes in bariatric patients. Methods: This longitudinal observational study of 85 patients with obesity undergoing bariatric surgery included 41 cases with depression and 44 controls. Before and 6 months after surgery, we assessed depression by clinical interview and measured serum high-sensitivity C-reactive protein (hsCRP) and inflammatory cytokines, including interleukin (IL)-6 and IL-10. Results: Before surgery, depression diagnosis was associated with significantly higher serum hsCRP, IL-6, and IL-6/10 ratio levels after controlling for confounders. Six months after surgery, patients with pre-existing depression still had significantly higher inflammation despite demonstrating similar weight loss to controls. Hierarchical regression showed higher baseline hsCRP levels predicted poorer weight loss (β = −0.28, p = 0.01) but had no effect on depression severity at follow-up (β = −0.02, p = 0.9). Instead, more severe baseline depressive symptoms and childhood emotional abuse predicted greater depression severity after surgery (β = 0.81, p < 0.001; and β = 0.31, p = 0.001, respectively). Conclusions: Depression was significantly associated with higher inflammation beyond the effect of obesity and other confounders. Higher inflammation at baseline predicted poorer weight loss 6 months after surgery, regardless of depression diagnosis. Increased inflammation, rather than depression, may drive poor weight loss outcomes among bariatric patients. [ABSTRACT FROM AUTHOR]

This article argues that Durham, North Carolina configures itself as a place for weight loss through its dieting industry and its identity as the "Diet Capital of the World." Building from archival data from the 1930s through the 1980s, I trace the historical development of Durham's diet industry. Following work in crip studies this article theorizes weight loss as a "cure" that works to remove fatness from individual bodies and remove fat people from the future. Engaging with work in urban geography and critical geographies of fatness, this article analyzes how anti-fatness and place co-produce each other across scales in the city. The Rice Houses and Durham's broader dieting landscape illustrate how places are created for spatial and temporal disciplining of fat bodies. Attending to these sites, this article understands how anti-fat cure constructs places to discipline fat people's bodies and create futures without fatness. [ABSTRACT FROM AUTHOR]

Purpose: Overweight and obesity are common in Australia and among the leading risk factors for ill health. Maintained weight loss of > 5– 10% can prevent and reduce the risk of obesity-related comorbidities. Prescription weight loss medications plus lifestyle interventions can result in additional weight loss compared with lifestyle interventions alone, but these medications are under-prescribed in Australia. Our aim was to develop a greater understanding of the treatment preferences of people with overweight or obesity and the healthcare practitioners (HCPs) who treat them. Participants and Methods: An online survey of Australian adults with overweight or obesity and treating HCPs was conducted in 2020. A discrete choice experiment (DCE) approach was used to determine what is most important to people when evaluating oral and injectable prescription weight loss medications. Participants were asked to choose between three hypothetical treatment alternatives: "Oral pill"; "Subcutaneous injection pen (replaceable needle)"; "Disposable subcutaneous injection pen (hidden needle)"; and an opt-out option ("None of these"). Results: The online survey and DCE were completed by 193 patients and 104 HCPs. For both patients and HCPs, all treatment alternatives (oral, replaceable injection and disposable injection) were preferred over the opt-out. Gastrointestinal side effects, followed by success rate, percentage body weight lost, and cost were the most important attributes to patients. For HCPs, percentage body weight loss was the most important treatment attribute, followed by success rate, gastrointestinal side effects and cost. While most patients reported relatively low needle fear, physicians reported relatively high perceived patient needle fear. Conclusion: Clinician-patient discussions about treatments for weight loss should cover the option of prescription weight loss medications, including injectable medications, which patients may be less apprehensive about than physicians believe. Treatments with a high success rate and low or manageable risk of gastrointestinal side effects may be preferred over alternatives. Plain Language Summary: Overweight and obesity are the leading cause of health problems in Australia. Medications can be effective for people with this condition when combined with diet and exercise changes, but weight-loss medications in Australia are under-used. To understand why, we surveyed 193 people living with overweight and obesity ("patients"), and 104 healthcare professionals ("HCPs"/doctors) who prescribe weight-loss medications. The online survey asked patients and HCPs to choose between medications with different benefits and risks, to uncover what features are most important to them (eg, would they prefer a medication that helps lose more weight, even if it means more side effects?). We found that both patients and HCPs would prefer to take/prescribe weight-loss medication than go medication-free. Patients preferred to take medications with low risk of gastrointestinal side effects (nausea, diarrhea/vomiting), that would help them lose the most amount of weight, and were not too expensive. HCPs preferred to prescribe medications that would help their patients lose the most amount of weight, that had the highest chance of success, had low risk of gastrointestinal side effects, and low-cost. HCPs also thought patients were more afraid of injectable medications than they actually were (most patients said they did not mind injections). If HCPs have a better understanding of what their patients want from weight-loss medication, they can have more meaningful conversations and offer medications which align with patients' personal values and long-term health goals. With this approach, patients are more likely to stick with treatment, which means better long-term results. [ABSTRACT FROM AUTHOR]

This study aimed to evaluate the efficacy of Lactobacillus delbrueckii ssp. bulgaricus (L. bulgaricus) in improving body weight, obesity-related outcomes, and lipid profiles of overweight people. Thirty-six overweight participants were randomly assigned to either a probiotic or a placebo group. A placebo powder or L. bulgaricus powder (containing 1 × 108 colony-forming unit (CFU) of the probiotic) was administered daily for 12 weeks. Body composition was determined, and blood tests were performed before and after the intervention. L. bulgaricus supplementation under the present condition did not affect the body weight, fat percentage, or body mass index (BMI) of the participants, while it resulted in a notable decrease in blood triglyceride (TG) levels, which corresponded to a lowering of the TG proportion in the composition of large VLDL (L–XXL sized fractions) and HDL (M and L fractions) in the probiotic-treated group. These results suggest that L. bulgaricus supplementation under the current conditions may not be helpful for losing weight, but it has the potential to decrease blood TG levels by modulating TG accumulation in or transport by VLDL/HDL in obese patients. L. bulgaricus supplements may have health-promoting properties in preventing TG-related diseases in overweight people. [ABSTRACT FROM AUTHOR]

I provide novel evidence on the role of imperfect information in shaping childhood obesity. Between 2003 and 2017, 24 states began requiring schools to perform Body Mass Index assessments on students. Using the 1991 to 2017 National and State Youth Risk Behavior Surveys and a stacked difference‐in‐differences identification strategy, I show that these state‐mandated school‐based BMI assessments were associated with an increase in the likelihood that teens described themselves as overweight and reported that they were trying to lose weight. The relationship was most pronounced for overweight teens, suggesting that the assessments improved awareness about BMI status among this group, though I also find that non‐overweight teen girls were subsequently more likely to incorrectly describe themselves as overweight. While I do not detect meaningful changes in exercise or calorie‐limiting behaviors, I do find that these state‐mandated school‐based BMI assessments were associated with a modest reduction in BMI. [ABSTRACT FROM AUTHOR]

Background: Obesity is now an emerging public health challenge in Nigeria, because of changing lifestyle. However, there are variations on the reported prevalence of obesity. This study determined the prevalence of overweight and obesity among school children in Mainland Local Government Area, Lagos. Materials and Method: A cross-sectional survey among children seen at primary schools in Mainland Local Government Area, Lagos State. Socio-demographic and anthropometric data were collected. BMI-for-age and sex Z-scores were determine and used to classify overweight/obese children. Results: A total of 340 pupils with a mean age of 8.61 ± 2.2 years were enrolled in the study. The majority were male (53.3%), from low socio-economic class (53.4%), and had low physical activity (58.89%). Thirty-four pupils (10.2%) were either overweight (6.9%) or obese (3.3%). The mean BMI (kg/m2) of the female pupils was 20.53 ± 1.51while that of the male pupils was 19.81 ± 1.43 (p = 0.002) Conclusion: The prevalence of Overweight/Obesity of 10.2% among the school pupils was relatively high confirming the reported emerging trend in low-income countries like Nigeria. The majority of the Pupils had low physical activity levels. Activities promoting weight loss are recommended to prevent the emergence of the obesity epidemic. [ABSTRACT FROM AUTHOR]

Copyright of Heart & Vascular Diseases / Choroby Serca & Naczyn is the property of VM Medica-VM Group (Via Medica) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction: This systematic review has been undertaken in order to assess the effects of hypocaloric, highprotein diets on weight loss and cardiovascular risk factors such as serum lipid levels in metabolically healthy obese adults. The primary outcomes measured include changes in pre-and post-diet mean BMI, LDL-C, HDL-C, TAG, and TC levels. Methods: Four databases including: Embase, MEDLINE (via PubMed), Cochrane and Web of Science were searched with no restrictions on language or publication period. Clinicaltrials.gov was also searched in order to identify unpublished or on-going studies. Results: Three of four studies included in this systematic review noted a significantly greater loss in pre- and post-diet mean BMI levels in the hypocaloric, high-protein diet group as compared to hypocaloric, non-high protein diets (control). Whilst pre- and post-diet mean LDL-C, HDL-C, TAG, and TC levels did not differ significantly among hypocaloric, high-protein and control diet groups. Conclusion: Hypocaloric, high-protein diets had an unclear effect on blood-lipid levels as compared to control. Weight loss however was significantly greater in the hypocaloric, high-protein group as compared to other hypocaloric, non-high-protein diet groups. [ABSTRACT FROM AUTHOR]

Aims: To determine the relationship between exposure and weight‐loss trajectories for the glucagon‐like peptide‐1 analogue semaglutide for weight management. Materials and Methods: Data from one 52‐week, phase 2, dose‐ranging trial (once‐daily subcutaneous semaglutide 0.05–0.4 mg) and two 68‐week phase 3 trials (once‐weekly subcutaneous semaglutide 2.4 mg) for weight management in people with overweight or obesity with or without type 2 diabetes were used to develop a population pharmacokinetic (PK) model describing semaglutide exposure. An exposure‐response model describing weight change was then developed using baseline demographics, glycated haemoglobin and PK data during treatment. The ability of the exposure‐response model to predict 1‐year weight loss based on weight data collected at baseline and after up to 28 weeks of treatment, was assessed using three independent phase 3 trials. Results: Based on population PK, exposure levels over time consistently explained the weight‐loss trajectories across trials and dosing regimens. The exposure‐response model had high precision and limited bias for predicting body weight loss at 1 year in independent datasets, with increased precision when data from later time points were included in the prediction. Conclusion: An exposure‐response model has been established that quantitatively describes the relationship between systemic semaglutide exposure and weight loss and predicts weight‐loss trajectories for people with overweight or obesity who are receiving semaglutide doses up to 2.4 mg once weekly. [ABSTRACT FROM AUTHOR]

Background: Since bariatric surgery results in massive weight loss, it may be associated with a disproportionate decrease in lean body mass. Objective: To evaluate body composition in post-bariatric surgery patients who had a successful weight loss at 12 months (>50% excess weight loss) with comparisons to healthy controls who were matched for age, sex and BMI. Methods: This is an observational analytic study using data from post-bariatric surgery patients who had laparoscopic Roux-en-Y gastric bypass (RYGB) or laparoscopic sleeve gastrectomy (SG) at King Chulalongkorn Memorial Hospital. Patients who had percentage excessive weight loss (%EWL) >50% and achieved a BMI of <30 kg/m2 within 12 months after the surgery were included. Non-operative healthy controls matched for sex, age, and BMI (1:1) were recruited. The 12-month post-bariatric surgery BMI was used to match the BMI of the control subjects. A single bioelectrical impedance analysis (BIA) (Inbody 770) machine was used for the entire study. Results: Sixty participants were included in this study. There are 30 post-bariatric surgery patients (female n = 19, male n = 11) and 30 non-operative controls (female n = 19, male n = 11). The 12-month post-bariatric surgery patients had lower percentage of body fat (PBF) (30.6% vs 35.9%, P -value.001) and trunk fat mass (10.3 vs 12.4 kg, P -value.04) than non-operative controls. The 12-month post-bariatric surgery patients also were found to have more soft lean mass (SLM) (47.7 vs 39.9 kg, P -value.001), fat free mass (FFM) (51.1 vs 42.3 kg, P -value.001), skeletal muscle mass (SMM) (27.5 vs 23 kg, P -value.003), and trunk lean mass (21.2 vs 19 kg, P -value.02). Conclusion: Despite the significant reductions in all body composition variables in post-bariatric surgery patients at 12-month follow-up, both fat free mass and skeletal muscle mass were found to be higher in the surgical patients compared to the control group. Clinical trials: Thai Clinical Trials Registry, https://thaiclinicaltrials.org/ ID:TCTR20200223003 [ABSTRACT FROM AUTHOR]

Over the past 50 years, the number of overweight/obese people increased significantly, making obesity a global public health challenge. Apart from rare monogenic forms, obesity is a multifactorial disease, most likely resulting from a concerted interaction of genetic, epigenetic and environmental factors. Although recent studies opened new avenues in elucidating the complex genetics behind obesity, the biological mechanisms contributing to individual's risk to become obese are not yet fully understood. Non-genetic factors such as eating behaviour or physical activity are strong contributing factors for the onset of obesity. These factors may interact with genetic predispositions most likely via epigenetic mechanisms. Epigenome-wide association studies or methylomewide association studies are measuring DNA methylation at single CpGs across thousands of genes and capture associations to obesity phenotypes such as BMI. However, they only represent a snapshot in the complex biological network and cannot distinguish between causes and consequences. Intervention studies are therefore a suitable method to control for confounding factors and to avoid possible sources of bias. In particular, intervention studies documenting changes in obesity-associated epigenetic markers during lifestyle driven weight loss, make an important contribution to a better understanding of epigenetic reprogramming in obesity. To investigate the impact of lifestyle in obesity state specific DNA methylation, especially concerning the development of new strategies for prevention and individual therapy, we reviewed 19 most recent human intervention studies. In summary, this review highlights the huge potential of targeted interventions to alter disease-associated epigenetic patterns. However, there is an urgent need for further robust and larger studies to identify the specific DNA methylation biomarkers which influence obesity. [ABSTRACT FROM AUTHOR]

Psychiatric comorbidity is common among the bariatric population although the prognostic significance of psychiatric comorbidity on outcomes is uncertain. This prospective study examined differences in weight and psychosocial functioning outcomes based on lifetime and current (post-surgical) psychiatric comorbidity. Participants were 140 adults in a RCT for loss-of-control (LOC)-eating approximately six months post-bariatric surgery. Two structured interviews were administered: the Eating Disorder Examination-Bariatric Surgery Version (EDE-BSV) to assess LOC-eating and eating-disorder psychopathology, and the Mini International Neuropsychiatric Interview (MINI) to assess lifetime and current (post-surgical) psychiatric disorders. The EDE-BSV and Beck Depression Inventory (BDI-II) were repeated at post-treatment and 24-month follow-ups. Lifetime (75.7%) and current/post-surgical (25%) psychiatric diagnoses were common. Groups with and without psychiatric comorbidity did not differ significantly in weight loss outcomes at any timepoint but psychiatric comorbidity was associated significantly with greater LOC-eating, eating-disorder psychopathology, and depression. Among participants with LOC-eating post-bariatric surgery, lifetime and post-surgical psychiatric comorbidity was not associated with acute or longer-term weight outcomes but predicted poorer psychosocial functioning. Findings challenge prevailing views that psychiatric comorbidity is related to poorer longer-term weight outcomes following bariatric surgery but highlight its clinical significance as it is associated with broad psychosocial difficulties. [ABSTRACT FROM AUTHOR]

Bariatric interventions (BI, including surgical interventions) are effective in patients with massive obesity, i.e., a body mass index (BMI) > 40, and their number has steadily increased during the past decade. Yet, the stability of improvements in quality of life (QoL) in post-interventional patients is understudied and restricted to studies with small samples and short follow-ups. Patients with BI between 2004 and 2018 were identified in a health claims database and invited to fill in a survey, comprising sociodemographic and lifestyle information and psychometric scales. QoL was assessed with the Bariatric QoL (BQL) scale with lower scores denoting worse QoL. BMI and excess weight loss (EWL) were calculated for the time soon after intervention (EWL-T1) and when filling the survey (EWL-T2). The majority of n = 2151 patients were female (80.7 %), had a mean age of 54.5 years and a mean BMI of 34.8. The mean EWL-T1 was 79 % (EWL-T2: 64.6 %). The mean BQL score was 47.6 and decreased with BMI (18.5–24.9: 52.6 vs. > 40: 38.7), EWL-T2 (>66 %: 51.3 vs. <65 %: 42.1) and years since intervention (3–4: 48.2 vs > 8: 45.1, each p <.001). For EWL-T1, the association between higher EWLs and higher BQL scores was stronger in females than in males (p <.005); for EWL at T2, both sexes did not differ in this regard (p =.848). Among normal-weight persons, males scored significantly lower on the BQL than females (44.9 vs. 54.9). Post-interventional QoL improvements diminish over time and depend on the weight loss, with significant differences between men and women. [ABSTRACT FROM AUTHOR]

The efficacy of using time restricted eating (TRE) for weight management and to mitigate metabolic disorders in overweight and obese people remains debatable. This meta-analysis quantified the impact of TRE on weight loss and metabolic health in overweight and obese people. The pooled results were subjected to a random-effects modeling using Hartung-Knapp-Sidik-Jonkman (HKSJ) method. Additionally, subgroup analysis was conducted based on study types, randomized controlled trials (RCTs) vs. non-randomized studies of interventions (NRSIs). Pooled results showed that subjects on TRE regimen (> 4 weeks) achieved a significant weight loss in comparison with unrestricted time regimen (weighted mean difference: −2.32%; 95% CI: −3.50, −1.14%; p < 0.01); however, weight loss was mainly attributed to the loss of lean mass rather than fat mass. The magnitude of weight loss was inversely correlated with daily fasting duration in RCTs. TRE significantly decreased the diastolic blood pressure and fasting insulin. An increase of low-density lipoprotein cholesterol (LDL-C) was observed in the TRE group. Favorable effect of TRE was observed on glucose metabolism but not on lipid profiles independent of weight loss. Hence TRE shall be administered with caution to overweight and obese people who have comorbidities such as dyslipidemia and sarcopenia. Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2021.1974335 [ABSTRACT FROM AUTHOR]

Aim: Randomized trials reporting 5‐year outcomes have shown bariatric surgery to induce diabetes remission and improve cardiovascular risk. However, the longer‐term effects of surgery are uncertain, with only one randomized trial reporting 10‐year diabetes outcomes in people with obesity. We aimed to compare 10‐year diabetes outcomes of people who are overweight but not obese, randomly assigned to receive either multidisciplinary diabetes care, or multidisciplinary diabetes care combined with gastric band (GB) surgery. Methods: Between 2009 and 2011, 51 adults were randomized. After 5 years, they were discharged to receive community care and reassessed after 10 years. The primary outcome was diabetes remission, defined as glycated haemoglobin (HbA1c) <6.5% (48 mmol/mol) without glucose‐lowering medication. Results: Forty‐one participants (20 medical and 21 GB) completed the 10‐year assessment. The median (Q1, Q3) weight loss in the GB group was 9.8 (6.7, 16.3)% at 10 years compared with 5.6 (3.4, 7.6)% in the medical group (median difference 4.2%; p =.008). Diabetes remission occurred in five GB participants and no medical participants (relative risk 0.76, 95% CI: 0.55‐0.93, p =.048). GB participants used fewer glucose‐lowering medications at 10 years but HbA1c, fasting glucose, calculated cardiovascular risk, quality‐of‐life and incident diabetes complications did not differ significantly between the groups. Conclusion: When compared with medical care, GB surgery achieved greater weight loss and modestly increased the likelihood of diabetes remission. However, it did not improve HbA1c, cardiovascular risk or quality of life. [ABSTRACT FROM AUTHOR]

Background: Some patients with overweight or obesity are not eligible for surgery according to international guidelines or do not wish a surgical intervention. For these patients, different treatment options are being explored. In this study, we examined the effectiveness of the swallowable intragastric balloon (IB) combined with lifestyle coaching, in patients living with overweight and obesity. Method: A retrospective data study was conducted on patients with a swallowable IB placement between December 2018 and July 2021, combined with a 12-month coaching program. Before balloon placement, patients underwent multidisciplinary screening. The IB was swallowed and filled with fluid once in the stomach and naturally excreted around 16 weeks. Results: A total of 336 patients, 71.7% female, were included with a mean age of 45.7 (±11.7) years. Mean baseline weight and BMI were 107.54 (±19.16) kg and 36.1 (±5.02) kg/m2. After 1 year, the mean total weight loss was 11.0% (±8.4). The mean placement duration was 13.1 (±2.82) min, and in 43.7%, a stylet was used to facilitate placement. The most common symptoms were nausea (80.4%) and gastric pain (80.3%). In the majority of patients, complaints were resolved within a week. The early deflation of the balloon occurred in 8 patients (2.4%) of which one showed symptoms suggesting a gastric outlet obstruction. Conclusion: Given the low rate of long-term complaints while providing a positive effect on weight loss, we conclude that the swallowable intragastric balloon, combined with lifestyle coaching, is a safe and effective treatment option for patients living with overweight and obesity. [ABSTRACT FROM AUTHOR]

Background: Obesity is linked to a higher incidence of Alzheimer's disease (AD). Studies show that plasma amyloid-β (Aβ) dyshomeostasis, particularly low 42/40 ratio indicates a heightened risk for developing AD. However, the relationship between body mass index (BMI) and circulating plasma Aβ has not been extensively studied. Objective: We hypothesized that people with a high BMI have altered plasma Aβ homeostasis compared with people with a lower BMI. We also tested whether reducing BMI by calorie-restriction could normalize plasma concentrations of Aβ. Methods: Plasma concentrations of Aβ40, Aβ42, and Aβ42/40 ratio were measured in 106 participants with BMIs classified as lean, overweight, or obese. From this cohort, twelve participants with overweight or obese BMIs entered a 12-week calorie-restriction weight loss program. We then tested whether decreasing BMI affected plasma Aβ concentrations. Results: Plasma Aβ42/40 ratio was 17.54% lower in participants with an obese BMI compared to lean participants (p < 0.0001), and 11.76% lower compared to participants with an overweight BMI (p < 0.0001). The weight loss regimen decreased BMI by an average of 4.02% (p = 0.0005) and was associated with a 6.5% decrease in plasma Aβ40 (p = 0.0425). However, weight loss showed negligible correlations with plasma Aβ40, Aβ42, and Aβ42/40 ratio. Conclusion: Obesity is associated with aberrant plasma Aβ homeostasis which may be associated with an increased risk for AD. Weight loss appears to lower Aβ40, but large-scale longitudinal studies in addition to molecular studies are required to elucidate the underlying mechanisms of how obesity and weight loss influence plasma Aβ homeostasis. [ABSTRACT FROM AUTHOR]

Obesity is one of the world's diseases that endanger human health, causing systemic inflammation caused by excessive reactive oxygen damage. An increase in the proportion of obese people with reduced sperm motility has been reported. But the mechanism behind it remains unclear. Peroxiredoxin 2 (PRDX2) is a member of the peroxidase family that effectively removes hydrogen peroxide. This study is to clarify the expression of PRDX2 in the testes of obese mice and lay a foundation for further exploration of the regulatory and protective effects of PRDX2 on spermatogenesis. A model of high-fat-induced obesity in animals was constructed, and the expression of PRDX2 in the testes of the two groups was detected by immunohistochemistry, western blotting, immunofluorescence and other techniques. Hydrogen peroxide (H 2 O 2) and cholesterol were co-cultured in testicular support cells for 48 h to observe the expression of PRDX2. PRDX2 expression was reduced in the testes of the obese group, and immunohistochemistry showed that it was mainly localized to supporting cells. H 2 O 2 inhibits the expression of PRDX2 in Sertoli cells, and high cholesterol upregulates the expression of PRDX2 in Sertoli cells. PRDX2 has some antioxidant properties against changes in the testicular environment caused by HFD. And under short-term oxidative stress to enhance its antioxidant capacity. PRDX2 may be involved in maintaining the oxidative balance of the spermatogenesis environment. • Describe the relationship between PRDX2 and spermatogenesis in mice of obesity induced asthenospermia. • Provide new treatment ideas for patients with obesity and asthenospermia. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS: In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. RESULTS: Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. CONCLUSIONS: Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure. [ABSTRACT FROM AUTHOR]

Introduction and aim. Serum ceruloplasmin level may be a biomarker associated with obesity and cardiovascular risk. We aimed to evaluate the effect of body weight lost by diet and exercise program on metabolic parameters and serum ceruloplasmin levels in obese patients. Material and methods. A total of 120 obese patients with BMI ≥30 kg/m² were enrolled in a 16-week balanced diet program with the goal of losing 10% or more of body weight while maintaining a daily energy deficit of 500-1000 kcal/day. Results. Mean weights of the patients decreased from 93.2±15.1 kg to 83.2±13.1 kg (p<0.001) and mean BMI decreased from 35.8±5.6 kg/m² to 31.9±4.9 kg/m² (p<0.001). Mean ceruloplasmin decreased from 25.2±4.7 mg/dL to 23.6±4.9 mg/dL (p<0.001), mean total cholesterol from 191.8±37.1 mg/dL to 153.8±28.7 mg/dL (p<0.001), mean LDL from 120.3±31.4 mg/dL to 91.1±27.7 mg/dL (p<0.001) and mean fasting blood glucose from 108.2±35 mg/dL to 103.3±81.1 mg/dL (p<0.001). There was a statistically significant and weak correlation between the change in ceruloplasmin and the change in BMI (p=0.016, R=0.233). There was a statistically significant and weak correlation between ceruloplasmin change and weight change (p=0.010, R=0.251). Conclusion. Obese patients' serum ceruloplasmin levels were found to decrease with weight loss. [ABSTRACT FROM AUTHOR]

Novo Nordisk's amycretin, a GLP-1 and amylin receptor agonist, showed promising results in a phase 1b/2a clinical trial for individuals with overweight or obesity. The trial demonstrated significant weight loss of up to 22% in participants receiving amycretin compared to those on a placebo. The safety profile of amycretin was similar to other incretin-based therapies, with gastrointestinal events being the most commonly reported adverse effects. Novo Nordisk plans to continue developing amycretin for the treatment of overweight and obesity based on these positive trial results. [Extracted from the article]

The article discusses the phase 2 data on the investigational drug Maridebart Cafraglutide (MariTide) by Amgen for the treatment of obesity and type 2 diabetes. The study enrolled 592 adults with obesity or overweight, with or without T2D, and showed promising results in terms of weight loss and glycemic control. Participants experienced up to approximately 20% weight loss in the group without T2D and up to approximately 17% weight loss in the group with T2D, along with improvements in HbA1C levels. The findings suggest the potential for further weight loss beyond the study period. [Extracted from the article]

Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists are hugely effective in the treatment of obesity. Originally developed for type 2 diabetes (T2D), these drugs cause dramatic weight loss in people with overweight or obesity, but how do they work, and are these therapeutics the long-sought-after solution to obesity? Here we explain the mechanisms of action of GLP-1R agonists in the context of weight loss and discuss their importance as therapeutics for obesity treatment. [ABSTRACT FROM AUTHOR]

Introduction: Behavioral strategies have been adding to the effectiveness of obesity treatment. And the assessment of the decisional balance (DB) for weight reduction, that is, the balance between expected losses and gains around the behavioral changes, is strategic for managing obesity. The DB assessment may contribute to the agreement on strategies to face the challenges of the treatment. But, there is a need to use a valid instrument to assess the DB. Objective: evaluate the quality of instruments assessing DB for weight reduction to qualify obesity management in the Sistema Único de Saúde - SUS (Unified Health System). Methods: A systematic review of studies about instrument development and/or validation was carried out on seven databases using the Cosmin methodology. Terms related to psychometrics, obesity, and DB were combined with Boolean operators to guide the search. Two researchers performed independently and in duplicate: data extraction, quality assessment, and evidence synthesis, and divergences were resolved by consensus. This review was registered in the international database Prospero (CRD42020197797). Results: Five studies were identified. Three of them reported translations and cross-cultural validity of the same instrument. All analyses presented DB in two dimensions (pros and cons), but used doubtful or inadequate methods. Most of the evidence was very low rate. Conclusions: The results did not support the instrument's use, translations, or cross-cultural adaptation. It is necessary to develop a new tool. By providing a valid instrument for use in SUS, this study could contribute to qualifying the care of people with obesity and stopping the growth of obesity in the country. [ABSTRACT FROM AUTHOR]